אינטרקציה פקסלוביד ואייברנס

כן, קיימת אינטראקציה בין שתי התרופות, יש לחדש הטיפול באייברנס שלושה ימים אחרי הפסקת הטיפול בפקסלוביד. From LiverPool : Coadministration has not been studied. Palbociclib is metabolised by CYP3A and SULT2A1 and concentrations are expected to increase due to strong inhibition of CYP3A4 by nirmatrelvir/ritonavir. Itraconazole (a strong CYP3A4 inhibitor) increased palbociclib AUC by ~87%. A similar effect is expected with nirmatrelvir/ritonavir Coadministration with strong CYP3A4 inhibitors (such as nirmatrelvir/ritonavir) is not recommended. The decision to pause or dose-adjust palbociclib should be made in conjunction with the patient’s oncologist. If it is decided to pause palbociclib, start nirmatrelvir/ritonavir 24 hours after the last dose of palbociclib due to the long elimination half-life of palbociclib. Restart palbociclib 3 days after completing nirmatrelvir/ritonavir treatment given that CYP3A4 inhibition by ritonavir takes several days to resolve. Alternatively, if coadministration is necessary, consider reducing palbociclib by 40% (i.e., 75 mg once daily for patients on 125 mg once daily palbociclib) with close monitoring for toxicity. If dose reduction below 75 mg once daily is required, discontinue the treatment